Coherus Biosciences (CHRS) PT Lowered to $15 at Maxim Group

November 14, 2022 12:46 PM EST
Get Alerts CHRS Hot Sheet
Price: $1.20 +5.26%

Rating Summary:
    11 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy lowered the price target on Coherus Biosciences (NASDAQ: CHRS) to $15.00 (from $17.00) while maintaining a Buy rating.

You May Also Be Interested In





Related Categories

Analyst PT Change